Outstanding Achievement Award, Urologic Oncology Branch, National Cancer Institute, 2002
CIAO Award for Medicine, 1995
Chairman of the Prostate Committee of the National Cancer Institute’s Prostate, Lung,
Disclosure of Financial Interests with IndustryWashington University and its physicians are committed to ensuring integrity and objectivity in medical decision-making. Some of our physicians work collaboratively with pharmaceutical or medical device companies to develop innovative ideas and products that can improve health care delivery and clinical outcomes for patients. In some instances, our faculty physicians are paid by these commercial companies to provide advice on product design or to speak about the use of medications, devices, equipment or procedures. These payments may include: a) compensation for consulting and speaking engagements, b) equity, and/or c) royalties for products invented by our faculty. Any payments to Washington University physicians must be based on tangible services and may not exceed fair market value for their work. In addition to disclosure on this web site, physicians earning more than $10,000 per year must disclose their corporate financial relationship in writing to patients when prescribing or using that company's products.
Dr. Gerald L. Andriole reported the following earned financial interests during calendar year 2011. Move your mouse over a header for more info.
| Company | Royalties Royalties: When a faculty member invents or conceives a new or improved process or product, the company that manufactures the product will make royalty payments to the faculty member. Royalty payments usually are a small percentage of the company’s revenue related to that product. | Equity Equity: Equity is an ownership interest in a company. Faculty members may be paid for their service to a company in stock or the option to obtain stock. | Consulting &
Advisory Boards Consulting and Advisory Boards: Faculty may be paid to provide expertise to a company by being their consultant, or by serving on an advisory board. | Speaker Fees Speaker Fees: Companies may pay faculty to speak to professional audiences about their products. |
| Amgen | | | $10,001-$25,000 | |
| GlaxoSmithKline | | | $1,000-$10,000 | $1,000-$10,000 |
| Augmenix | | Yes | | |
| Envisioneering | | Yes | | |
| Cambridge Endosciences | | Yes | | |
To learn more about Washington University's policies on collaborations with industry,
click here.
Editorial Responsibilities
Editor or Editorial Boards:Associate Editor, The 5 Minute Urology Consult, 2008-present
Community Editor, Urologic Surgery, American College of Surgeons Web Portal, 2007-present
Editorial Board, Cornell University Medical College Reports on Men’s Urologic Health, 2006-present
Associate Editor, The Journal of Men’s Health & Gender, 2003-present
Urology Times, Hands-On Editor, 2002-present
Editor-in-Chief, Yearbook of Urology, 1997-present
Editorial Board, Urology Research and Treatment, 1999-present
Editorial Board, Urologia Internationalis, 1997-present
Editorial Consultant, The Paget Society, 1999-present
The Prostate Journal, 1997-present
Editorial Board, Infections in Urology, 1991-present
Editorial Advisory Board, Surgical Rounds, 1990-present
Editorial Board, Annals of Surgical Oncology, 1997-2003
Reviewer:
Journal of Urology
Urology
Urologic Oncology
Journal of the National Cancer Institute
Cancer
Cancer Research
New England Journal of Medicine
Journal of Clinical Oncology
Prostate Cancer
European Urology
Major National Committees
Steering Committee, Prostate Cancer Chemoprevention Trial
Steering Committee, NIH PLCO Cancer Screening Trial
Chairman, Prostate Subcommittee NCI PLCO Cancer Screening Trial
Medical Advisory Committee, Prostate Intervention Versus Observation Trial
(PIVOT)
Commission on Cancer of the American College of Surgeons
Cochrane Collaboration in Prostatic Diseases
AUA/Pfizer Visiting Professor Review Board
Steering Committee, CAMUS Trial (NIH/NIDDK)
Chairman, Steering Committee, REDUCE Trial (Dutasteride Chemoprevention Trial)
NCI, Biorepository Scientific Advisory Panel
Panel Member, Blue Ribbon Prostate Institution Oral Examiner, Exam Committee, American
Selected or Recent Journal Articles
Sandhu GS, Andriole GL. Active Surveillance for Prostate Cancer: Barriers to Widespread Adoption. Eur Urol. 2012 Jun 30.
Lai HH, North CS, Andriole GL, Sayuk GS, Hong BA. Polysymptomatic, polysyndromic presentation of patients with urological chronic pelvic pain syndrome. J Urol. 2012 Jun.
Sutcliffe S, Grubb Iii RL, Platz EA, Ragard LR, Riley TL, Kazin SS,
Hayes RB, Hsing AW, Andriole GL; on behalf of the Urologic Diseases in
America Project. Non-steroidal anti-inflammatory drug use and the risk of benign prostatic hyperplasia-related outcomes and nocturia in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. BJU Int. 2012 Mar 19.
Strope SA, Yang L, Nepple KG, Andriole GL, Owens PL. Population based comparative effectiveness of transurethral resection of the prostate and laser therapy for benign prostatic hyperplasia. J Urol. 2012 Apr.
Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR,
Fouad MN, Isaacs C, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA,
O'Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hsing AW,
Izmirlian G, Pinsky PF, Kramer BS, Miller AB, Gohagan JK, Prorok PC;
PLCO Project Team. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012 Jan 18.
Shteynshlyuger A, Andriole GL. Cost-effectiveness of prostate specific antigen screening in the United States: extrapolating from the European study of screening for prostate cancer. J Urol. 2011 Mar.
Andriole GL, Bostwick D, Brawley OW, Gomella L, Marberger M, Montorsi F,
Pettaway C, Tammela TL, Teloken C, Tindall D, Freedland SJ, Somerville
MC, Wilson TH, Fowler I, Castro R, Rittmaster RS; REDUCE Study Group. The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study. J Urol. 2011 Jan.
Strope SA, Andriole GL. Prostate cancer screening: current status and future perspectives. Nat Rev Urol. 2010 Sep.
Humphrey PA, Andriole GL. Prostate cancer diagnosis. Mo Med. 2010 Mar-Apr.
Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi
F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson
TH, Fowler IL, Rittmaster RS; REDUCE Study Group. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010 Apr 1.
Strope SA, Andriole GL. Update on chemoprevention for prostate cancer. Curr Opin Urol. 2010 May.
Shteynshlyuger A, Andriole GL. Prostate cancer: to screen or not to screen? Urol Clin North Am. 2010 Feb.
Andriole GL. The impact of prostate cancer and hormonal therapy on bone. Rev Urol. 2009 Fall.
Wolin KY, Luly J, Sutcliffe S, Andriole GL, Kibel AS. Risk of urinary incontinence following prostatectomy: the role of physical activity and obesity. J Urol. 2010 Feb.
Andriole GL. Overview of pivotal studies for prostate cancer risk reduction, past and present. Urology. 2009 May.